Former Chief Financial Officer at INC Research
Life Science Partner recruited David Gill, MBA to become Chief Financial Officer at EndoChoice. EndoChoice an Atlanta-based company providing physicians with gastrointestinal endoscopy, diagnostics, infection control and imaging products.
He was most recently CFO of INC Research, a publicly traded contract research organization. Previously Gill served as the CFO for TransEnterix, leading a $55 M Series B financing, relocating the company headquarters, and leading planning to scale up GMP manufacturing. As CFO for CTI Molecular Imaging, he raised a total of $213 M including an initial public offering to finance the rapid growth. He established a strategic relationship with Siemens that led to the acquisition of the CTI for $1 B.
In his new role at EndoChoice, Gill will work closely with CEO Mark Gilreath to oversee all corporate financial operations. “Gill understands how to use debt, public markets, and private equity to generate significant return for shareholders,” stated Tom Callaway, MD, Founder and President of Life Science Partner. “He has excelled in companies with highly varied technologies and global operations.”
Gill earned his Bachelor Degree in Accounting from Wake Forest University and his MBA from Emory University Goizueta Business School.